Cover Image
市場調查報告書

日本的學名藥市場:產業趨勢、競爭情形、機會、展望

Japan Generic Drug Market - Industry Trends, Competitive Landscape, Opportunities and Outlook

出版商 IMARC Services Pvt. Ltd. 商品編碼 359385
出版日期 內容資訊 英文 70 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
日本的學名藥市場:產業趨勢、競爭情形、機會、展望 Japan Generic Drug Market - Industry Trends, Competitive Landscape, Opportunities and Outlook
出版日期: 2016年05月22日 內容資訊: 英文 70 Pages
簡介

日本以金額為準成為全球第8名的學名藥市場。可是,到目前為止的日本學名藥的普及率,比美國和歐洲等其他的已發展的市場低。政府制定至2017學名藥的普及率達60%的目標。這對國內及外國的學名藥廠商來說,預計產生巨大的機會。

本報告提供日本的學名藥市場上過去、現在、未來市場趨勢詳細分析,市場促進要素,銷售趨勢,處方趨勢,市場結構,競爭情形,法規,主要企業,主要醫藥品,製造及展望等系統性資訊。

第1章 調查手法、市場定義

第2章 調查摘要

第3章 日本的學名藥市場:簡介

  • 學名藥是什麼?
  • 無名商標、品牌學名藥
  • 認證學名藥

第4章 日本的學名藥市場收益非常大的理由

  • 專利到期的重量級醫藥品
  • 人口高齡化的擴大伴隨的醫療費增加
  • 日本是學名藥的普及率最低的國家之一
  • 調劑學名藥的獎勵
  • 企業、供應商的大幅度的節約
  • 生技仿製藥

第5章 全球學名藥市場

  • 現在、過去的市場趨勢
  • 市場分類:各國
  • 市場預測
  • 最被處方的學名藥、品牌醫藥品

第6章 日本的學名藥市場

  • 現在、到目前為止的市場趨勢
  • 品牌醫藥品、學名藥的佔有率
  • 現在、過去、未來的銷售趨勢
  • 現在、過去、未來的銷售額 (數量) 趨勢

第7章 日本的學名藥市場:競爭情形

  • 競爭結構
  • 主要企業的銷售額分析
  • 通路分析:各流通管道

第8章 日本的學名藥市場:價值鏈分析

  • 研究、開發
  • 製造
  • 行銷
  • 流通

第9章 日本的學名藥產業上法規

  • 日本的學名藥的認證次序
  • 規格

第10章 日本的學名藥市場:主要的成功因素

第11章 日本的學名藥市場:

第12章 學名藥製造工廠的成立必要條件

  • 製造工程
  • 原料的必要條件
  • 機器、基礎設施的必要條件

第13章 日本的學名藥市場:主要企業簡介

  • Teva Pharmaceutical Ltd.
  • 澤井製藥
  • Nichi-Iko Pharmaceutical
  • Pfizer Japan Inc.
  • Meiji Seika Pharma
  • 東和藥品
  • Nipro
  • 富士藥品
  • 第一三共S發
  • 日本非專利

圖表

目錄
Product Code: SRP00116DO

Japan represents the world's eighth biggest market for generic drugs in terms of value. Generic drugs, however, have traditionally enjoyed a relatively lower penetration in Japan compared to other developed markets such as the United States and Europe. Historically, the lower penetration of generic drugs in japan was due to several reasons. These included - the perception of inferior quality of generic drugs, the preference of branded drugs among physicians and patients and the limited profits to be made by physicians from pharmaceutical price differentials by prescribing low priced generics. Generic drugs also remained less popular in Japan because of the lack of generic substitution rights by Japanese pharmacists, slower review times in the drug approval process and difficulties working with major pharmaceutical distributors - many of whom were closely tied to major branded drug manufacturers.

The landscape of the japan generic drug market, however, has changed noticeably over the last decade. The Japanese government has identified growth of the country's generic drug market as imperative to Japan's long-term economic health. The Japanese government, recognizing the country's increasing aging population as well as rising costs of branded drugs has begun instituting healthcare policy changes to cut their expenditures on medical costs. Drug costs account for around a fifth of the country's total medical expenses and reducing this burden has become a cornerstone of Japan's health administration policy. Substitution of low-cost generic drugs for innovator products has been identified as a strategy where major savings are possible. Driven by these initiatives, the penetration of generics has grown robustly over the past few years. The government has also made a target towards achieving a generic penetration of 60% by 2017. This is expected to create huge opportunities for both domestic and foreign generic manufacturers in Japan.

The report entitled “Japan Generic Drug Market - Industry Trends, Competitive Landscape, Opportunities and Outlook” represents an in-depth analysis on the historical, current and future trends in the generic drug market in Japan. This research report serves as an exceptional tool to understand the drivers, sales trends, prescription trends, market structure, competitive landscape, regulations, key players, key drugs, manufacturing and the outlook of generic drug market in Japan. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who want to gain an insight into the market for generic drugs in Japan.

Key Questions Answered:

  • What are generic drugs? How are they different from branded drugs?
  • How has Japan's generic drug market performed in recent years?
  • How have generic drugs performed compared to branded drugs?
  • What were the total sales and prescriptions for generic drugs in Japan?
  • Who are the key players in the Japanese generic drug market? How have they performed?
  • What is the structure of the Japanese generic drug market?
  • What is the pricing mechanism of generic drugs in Japan?
  • What is the value chain of generic drugs in Japan?
  • What are the regulations for generic drugs in Japan?
  • How are generic drugs distributed in Japan?
  • How are generic drugs manufactured?
  • What are the raw material and machinery requirements to manufacture generic drugs?
  • What are the drivers and challenges in the Japanese generic drug market?

Table of Contents

1. Research Methodology and Market Definitions

2. Report Summary

3. Japan Generic Drug Market-Introduction

  • 3.1. What are Generic Drugs?
  • 3.2. Unbranded and Branded Generic Drugs
  • 3.3. Authorized Generic Drugs

4. Why is the Japanese Generic Drug Market so Lucrative

  • 4.1. Blockbuster Drugs Going Off-Patent
  • 4.2. Rising Healthcare Costs Coupled with an Increasing Ageing Population
  • 4.3. Japan Has One of the Lowest Penetration of Generics
  • 4.4. Incentives for Dispensing Generics
  • 4.5. Significant Savings For Payers and Providers
  • 4.6. Biosimilars

5. Global Generic Drug Market

  • 5.1. Current and Historical Market Trends
  • 5.2. Market Breakup by Country
  • 5.3. Market Forecast
  • 5.4. Most Prescribed Generic and Branded Drugs

6. Japan Generic Drug Market

  • 6.1. Japan Pharmaceutical Market-Current, Historical and Future Market Trends
  • 6.2. Japan Pharmaceutical Market-Share of Branded and Generic Drug
  • 6.3. Japan Generic Drug Market-Current, Historical and Future Sales Trends
  • 6.4. Japan Generic Drug Market-Current, Historical and Future Volume Trends

7. Japan Generic Drug Market- Competitive Landscape

  • 7.1. Japan Generic Drug Market-Competitive Structure
  • 7.2. Japan Generic Drug Market-Sales Breakup of Key Players
  • 7.3. Japan Generic Drug Market-Distribution Breakup by Channels

8. Japan Generic Drug Market-Value Chain Analysis

  • 8.1. Research and Development
  • 8.2. Manufacturing
  • 8.3. Marketing
  • 8.4. Distribution

9. Regulations in Japan Generics Industry

  • 9.1. Approval Pathway of a Generic Drug in Japan
    • 9.1.1. Master File Scheme for Active Ingredients
    • 9.1.2. Equivalency Review
    • 9.1.3. Conformity Audit
  • 9.2. Certifications
    • 9.2.1. MAH (Market Authorization Holder) License for Product Approval
    • 9.2.2. FMA (Foreign Manufacturer Accredited) Certification for Product Approval
    • 9.2.3. DMF (Drug Master File) Registration
    • 9.2.4. GMP (Good Manufacturing Practices) Certification
    • 9.2.5. Manufacturer's License

10. Japan Generic Drug Market: Key Success Factors

11. Japan Generic Drug Market: Road Blocks

12. Requirements for Setting up a Generic Drug Manufacturing Plant

  • 12.1. Manufacturing Process
  • 12.2. Raw Material Requirements
  • 12.3. Machinery and Infrastructure Requirements

13. Japan Generic Drug Market-Key Company Profiles

  • 13.1. Teva Pharmaceutical Ltd.
  • 13.2. Sawai Pharmaceutical Co., Ltd.
  • 13.3. Nichi-Iko Pharmaceutical Co., Ltd.
  • 13.4. Pfizer Japan Inc.
  • 13.5. Meiji Seika Pharma
  • 13.6. Towa Pharmaceutical
  • 13.7. Nipro Pharma Corporation
  • 13.8. Fuji Pharma Co., Ltd.
  • 13.9. Daiichi Sankyo Espha Co., Ltd.
  • 13.10. Nihon Generic Co. Ltd.

List of Figures

  • Figure 3-1: Structure of the Pharmaceutical Industry
  • Figure 3-2: Classification of Generic Drugs
  • Figure 4-1: Penetration of Generic Drugs Across Various Developed Markets
  • Figure 5-1: Global: Generic Drug Market: Sales Value (in Billion US$), 2010-2015
  • Figure 5-2: Global: Generic Drug Market: Sales Volume (in Billion Units), 2010-2015
  • Figure 5-3: Global: Generic Drug Market: Sales Value Breakup by Country (in %), 2015
  • Figure 5-4: Global: Generic Drug Market: Sales Volume Breakup by Country (in %), 2015
  • Figure 5-5: Global: Generic Drug Market Forecast: Sales Value (in Billion US$), 2016-2021
  • Figure 5-6: Global: Generic Drug Market: Sales Volume (in Billion Units), 2016-2021
  • Figure 6-1: Japan: Pharmaceutical Market: Sales Value (in Billion JPY), 2010-2015
  • Figure 6-2: Japan: Pharmaceutical Market: Sales Volume (in Billion Units), 2010-2015
  • Figure 6-3: Japan: Pharmaceutical Market Forecast: Sales Value (in Billion JPY), 2016-2021
  • Figure 6-4: Japan: Pharmaceutical Market: Sales Volume (in Billion Units), 2016-2021
  • Figure 6-5: Japan: Pharmaceutical Market: Sales Volume Breakup of Branded and Generic Drugs (in %), 2010 and 2015
  • Figure 6-6: Japan: Pharmaceutical Market: Sales Value Breakup of Branded and Generic Drugs (in %), 2010 and 2015
  • Figure 6-7: Japan: Generic Drug Market: Sales Value (in Billion JPY), 2010-2015
  • Figure 6-8: Japan: Generic Drug Market Forecast: Sales Value (in Billion JPY), 2016-2021
  • Figure 6-9: Japan: Generic Drug Market: Sales Volume (in Billion Units), 2010-2015
  • Figure 6-10: Japan: Generic Drug Market Forecast: Sales Volume (in Billion Units), 2016-2021
  • Figure 7-1: Japan: Generic Drug Market: Sales Share of Top Players (in %), 2015
  • Figure 8-1: Japan: Generic Drug Market: Value Chain Analysis
  • Figure 9-1: Japan: Approval Pathway for a Generic Drug

List of Tables

  • Table 4-1: Japan: Sales (in Billion JPY) and Patent Expiry of Major Drugs Expected to Lose Patent Protection
  • Table 4-2: Japan: History of Major Government Policies to Encourage the Use of Generic Drugs
  • Table 5-1: Global: Generic Drug Market: Sales Volume and Growth of Major Markets, 2014
  • Table 5-2: Global: Generic Drug Market: Volume Performance of Top Generic Drugs (in Million Prescriptions), 2015
  • Table 5-3: Global: Branded Drug Market: Volume Performance of Top Branded Drugs (in Million Prescriptions), 2015
  • Table 7-1: Japan: Generic Drug Market: Sales Values of Key Manufacturers (in Million JPY), 2015
Back to Top